Leriglitazone is a

PPAR-gamma Peroxisome proliferator-activated receptor gamma (PPAR-γ or PPARG), also known as the glitazone reverse insulin resistance receptor, or NR1C3 (nuclear receptor subfamily 1, group C, member 3) is a type II nuclear receptor functioning as a transc ...

agonist and metabolite of the glitazone

pioglitazone Pioglitazone, sold under the brand name Actos among others, is an anti-diabetic medication used to treat type 2 diabetes. It may be used with metformin, a sulfonylurea, or insulin. Use is recommended together with exercise and diet. It is not ...

. It is developed for

adrenomyeloneuropathy Adrenomyeloneuropathy (AMN) is a rare hereditary neurodegenerative disorder that primarily affects the spinal cord and peripheral nerves, occurring in less than 1 in 40,000 people. It is characterised by progressive motor dysfunction and adrenal i ...

, and other neurodegenerative diseases.

Society and culture

Legal status

In January 2024, the

European Medicines Agency The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products ...

(EMA) recommended the refusal of the marketing authorization for leriglitazone (Nezglyal) requested by Minoryx Therapeutics S.L. In May 2024, the EMA confirmed its recommendation to refuse marketing authorization for leriglitazone. Leriglitazone was intended for the treatment of cerebral adrenoleukodystrophy.

References

Thiazolidinediones Experimental drugs {{Pharma-stub